LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Suletud

SektorTervishoid

16.62 -0.12

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.59

Max

16.71

Põhinäitajad
By Trading Economics
Sissetulek	117B 106B
Müük	100B 1.2T
P/E Sektori keskmine	71.13 51.415
Aktsiakasum	0.21
Dividenditootlus	4.04
Kasumimarginaal	8.697
Töötajad	47,455
EBITDA	140B 456B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+26.2% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	4.04% 2.34%

Turustatistika
By TradingEconomics
Turukapital	-3.6B 52B
Eelmine avamishind	16.74
Eelmine sulgemishind	16.62

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 15.16 Toetus ja vastupanu

Takeda Pharmaceutical Co Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2026, 08:59 UTC

Tulu

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29. jaan 2026, 07:11 UTC

Tulu

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19. dets 2025, 03:32 UTC

Suurimad hinnamuutused turgudel

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30. okt 2025, 09:39 UTC

Tulu

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30. okt 2025, 07:32 UTC

Tulu

Takeda Posts Quarterly Net Loss, Cuts Guidance

13. mai 2026, 06:57 UTC

Tulu

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13. mai 2026, 06:54 UTC

Tulu

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13. mai 2026, 06:44 UTC

Tulu

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13. mai 2026, 06:38 UTC

Tulu

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13. mai 2026, 06:31 UTC

Tulu

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13. mai 2026, 06:31 UTC

Tulu

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13. mai 2026, 06:31 UTC

Tulu

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13. mai 2026, 06:31 UTC

Tulu

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13. mai 2026, 06:31 UTC

Tulu

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13. mai 2026, 06:31 UTC

Tulu

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29. jaan 2026, 06:53 UTC

Tulu

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29. jaan 2026, 06:36 UTC

Tulu

Takeda Raises FY Revenue, Net-Profit Views

29. jaan 2026, 06:34 UTC

Tulu

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29. jaan 2026, 06:33 UTC

Tulu

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29. jaan 2026, 06:32 UTC

Tulu

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29. jaan 2026, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29. jaan 2026, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29. jaan 2026, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29. jaan 2026, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29. jaan 2026, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29. jaan 2026, 06:30 UTC

Tulu

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30. okt 2025, 07:10 UTC

Tulu

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30. okt 2025, 06:50 UTC

Tulu

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30. okt 2025, 06:49 UTC

Tulu

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30. okt 2025, 06:48 UTC

Tulu

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Võrdlus sarnastega

Hinnamuutus

Takeda Pharmaceutical Co Ltd ADR Prognoos

Hinnasiht

By TipRanks

26.2% tõus

12 kuu keskmine prognoos

Keskmine 21 USD 26.2%

Kõrge 21 USD

Madal 21 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Takeda Pharmaceutical Co Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Takeda Pharmaceutical Co Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 15.16Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.